Altamira Therapeutics (NASDAQ:CYTO) & Lipella Pharmaceuticals (NASDAQ:LIPO) Critical Comparison

Altamira Therapeutics (NASDAQ:CYTO) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for Altamira Therapeutics and Lipella Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altamira Therapeutics	0	0	0	0	0.00
Lipella Pharmaceuticals	0	0	1	0	3.00

Lipella Pharmaceuticals has a consensus target price of $16.00, suggesting a potential upside of 492.59%. Given Lipella Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Lipella Pharmaceuticals is more favorable than Altamira Therapeutics.

Insider and Institutional Ownership

1.9% of Altamira Therapeutics shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 13.0% of Altamira Therapeutics shares are held by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Altamira Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Profitability

This table compares Altamira Therapeutics and Lipella Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Altamira Therapeutics	N/A	N/A	N/A
Lipella Pharmaceuticals	-882.82%	-192.33%	-154.24%

Valuation and Earnings

This table compares Altamira Therapeutics and Lipella Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altamira Therapeutics	$320,000.00	3.19	-$4.31 million	N/A	N/A
Lipella Pharmaceuticals	$450,000.00	7.26	-$4.62 million	($4.25)	-0.64

Altamira Therapeutics has higher earnings, but lower revenue than Lipella Pharmaceuticals.

Summary

Lipella Pharmaceuticals beats Altamira Therapeutics on 7 of the 12 factors compared between the two stocks.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.